Earnings Release • Mar 9, 2022
Earnings Release
Open in ViewerOpens in native device viewer
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2022
Commission File Number: 001-35165
(Translation of registrant's name into English)
19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
This Form 6-K is incorporated by reference into the Company's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on April 22, 2019 (Registration No. 333-230979) and the Company's Registration Statement on Form F-3 filed with the Securities and Exchange Commission on September 17, 2021 (Registration No. 333-259610).
Exhibit Title 99.1 BrainsWay Reports Fourth Quarter and Full-Year 2021 Financial Results and Operational Highlights
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BRAINSWAY LTD. (Registrant)
Date: March 9, 2022 /s/ Christopher R. von Jako, Ph.D Christopher R. von Jako, Ph.D President and Chief Executive Officer
Revenue Growth of 34% in 2021, with Record Quarterly and Annual Revenues
Continued Progress in Expanding FDA Labeling for Deep TMS™ and Increasing Payor Coverage
Conference call to be held today, March 9, 2022, at 8:30 AM ET
BURLINGTON, Mass. and JERUSALEM, March 09, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported fourth quarter and full year 2021 financial results and provided an operational update.
"Our fourth quarter revenues reflect the continued solid execution by our team," stated Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay. "We generated \$29.7 million in revenue for full-year 2021, which represented a 34% increase over full-year 2020. Moreover, demand for our Deep TMS therapy in multiple indications led to a strong close to the year, as we generated \$8.5 million in revenue for the fourth quarter of 2021 – a robust 20% increase over our fourth quarter 2020. This is particularly noteworthy given the recent Omicron surge, and we have now demonstrated year-over-year growth in six consecutive quarters. We anticipate that the current positive operating trends that drove our significant momentum in 2021, highlighted by recent achievements on the commercial, clinical, regulatory, and reimbursement fronts, will lead to further growth for BrainsWay in 2022 and beyond."
"Importantly, we continue to achieve important progress in securing reimbursement for Deep TMS in OCD," continued Dr. von Jako. "Our most recent achievement in this arena was the final LCD issued by the Palmetto GBA MAC, which covers over 20% of the Medicare population and now brings the total number of covered lives eligible for Deep TMS OCD coverage to approximately 60 million. We also continue to publish compelling data on Deep TMS in multiple key areas, with our most recent publications highlighting our innovative technology in alcohol use disorder, OCD, and anxious depression."
BrainsWay's management will host a conference call on Wednesday, March 9, 2022, at 8:30 a.m. Eastern Time to discuss these results and answer questions.
Wednesday, March 9th, at 8:30 AM Eastern Time:
| United States: | 877-407-3982 |
|---|---|
| Israel: | 1 809 406 247 |
| International: | 1 201-493-6780 |
| Conference ID: | 13727217 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1530336&tp_key=1c81195bcb |
To listen to a live webcast, please visit the Investors section of the BrainsWay website at www.BrainsWay.com. Please access the Company's website at least 10 minutes ahead of the conference call to register. The webcast replay will be available on the website for two weeks following the completion of the call.
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company's anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company's intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications; continuation and/or exacerbation of the global supply chain crisis and its impact on the Company's ability to source components, meet customer demand, fill orders, maintain pricing levels and support the Company's service needs; and the effect of the global COVID-19 health pandemic on our business and continued uncertainty and market impact relating thereto.
Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward- looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 20-F. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
BrainsWay: Scott Areglado SVP and Chief Financial Officer 844-386-7001 [email protected]
Investors: Bob Yedid LifeSci Advisors 646-597-6989 [email protected]
| December 31, 2021 |
December 31, 2020 |
||||
|---|---|---|---|---|---|
| ASSETS | (Unaudited) | ||||
| Current Assets | |||||
| Cash and cash equivalents | \$ | 16,921 | \$ | 16,961 | |
| Short-term deposits | 40,428 | 221 | |||
| Trade receivables, net | 6,332 | 5,582 | |||
| Other current assets | 1,766 | 1,534 | |||
| Total current assets | 65,447 | 24,298 | |||
| Other long-term assets | 954 | 163 | |||
| System components | 4,463 | 3,642 | |||
| Leased systems | 3,813 | 5,198 | |||
| Other property and equipment | 1,055 | 710 | |||
| Total assets | \$ | 75,732 | \$ | 34,011 | |
| LIABILITIES AND EQUITY | |||||
| Current Liabilities | |||||
| Trade payables | \$ | 1,103 | \$ | 781 | |
| Other accounts payable | 4,792 | 3,769 | |||
| Deferred revenue | 2,195 | 1,543 | |||
| Liability in respect of research and development grants | 978 | 707 | |||
| Total current liabilities | 9,068 | 6,800 | |||
| Deferred revenue and other liabilities | 3,419 | 2,053 | |||
| Liability in respect of research and development grants | 5,921 | 5,524 | |||
| Total Liabilities | 18,408 | 14,377 | |||
| Equity: | |||||
| Share capital | 362 | 233 | |||
| Share premium | 137,566 | 95,135 | |||
| Share-based payment reserve | 5,340 | 3,748 | |||
| Currency Translation Adjustments | (2,188) | (2,188) | |||
| Accumulated deficit | (83,756) | (77,294) | |||
| Total Equity | 57,324 | 19,634 | |||
| Total Liabilities and Equity | \$ | 75,732 \$ | 34,011 |
| For the twelve months ended December 31, |
For the three months ended December 31, |
|||||||
|---|---|---|---|---|---|---|---|---|
| 2021 | 2020 | 2021 | 2020 | |||||
| (Unaudited) | (Unaudited) | |||||||
| Revenues | \$ | 29,657 | \$ | 22,057 | \$ | 8,470 | \$ | 7,066 |
| Cost of revenues | 6,599 | 5,058 | 1,906 | 1,566 | ||||
| Gross profit | 23,058 | 16,999 | 6,564 | 5,500 | ||||
| Research and development expenses, net | 6,393 | 5,823 | 2,032 | 1,576 | ||||
| Selling and marketing expenses | 15,880 | 11,283 | 4,518 | 2,999 | ||||
| General and administrative expenses | 5,784 | 4,722 | 1,466 | 1,332 | ||||
| Total operating expenses | 28,057 | 21,828 | 8,016 | 5,907 | ||||
| Operating loss | (4,999) | (4,829) | (1,452) | (407) | ||||
| Finance expense, net | (1,420) | (319) | (379) | (239) | ||||
| Loss before taxes on income | (6,419) | (5,148) | (1,831) | (646) | ||||
| Taxes on income | 43 | 237 | (484) | (240) | ||||
| Net loss | \$ | (6,462) | \$ | (5,385) | \$ | (1,347) | \$ | (406) |
| Basic and diluted net loss per share | \$ | (0.21) | \$ | (0.24) | \$ | (0.04) | \$ | (0.02) |
| For the twelve months ended December 31, |
|||||
|---|---|---|---|---|---|
| 2021 | 2020 | ||||
| (Unaudited) | |||||
| Cash flows from operating activities: | |||||
| Net loss | \$ | (6,462) | \$ | (5,385) | |
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | |||||
| Adjustments to profit or loss items: | |||||
| Depreciation and amortization | 560 | 438 | |||
| Depreciation of leased systems | 1,126 | 1,180 | |||
| Impairment and Destructions | 1,295 | 1,061 | |||
| Withdrawal of lease due to termination of contract Finance expenses, net |
- 1,420 |
(5) 319 |
|||
| Cost of share based payment Taxes on income |
1,893 43 |
799 237 |
|||
| Changes in asset and liability items: | |||||
| Increase in trade receivables | (849) | (7) | |||
| Increase in other assets | (1,226) | (97) | |||
| Increase (decrease) in trade payables | 289 | (552) | |||
| Increase in other accounts payable | 815 | 515 | |||
| Increase in deferred revenues and other liabilities | 2,039 | 320 | |||
| Cash paid and received during the year for: | |||||
| Interest paid | (62) | (71) | |||
| Interest received | 17 | 61 | |||
| Taxes on income paid | (14) | (249) | |||
| Cash provided by (used in) operating activities: | 884 | (1,436) | |||
| Cash flows from investing activities: | |||||
| Purchase of property and equipment and system components, net | (2,238) | (2,470) | |||
| Investment in short-term deposits | (40,000) | - | |||
| Investment in long-term deposits | 22 | 5 | |||
| Net cash used in investing activities | (42,216) | (2,465) | |||
| Cash flows from financing activities: Repayment of liability in respect of research and development grants |
(761) | (655) | |||
| Receipt of government grants | 492 | 42 | |||
| Repayment of lease liability | (475) | (417) | |||
| Issuance of share capital | 42,260 | - | |||
| Net cash provided by (used in) financing activities | 41,516 | (1,030) | |||
| Exchange rate differences on cash and cash equivalents | (224) | 218 | |||
| Decrease in cash and cash equivalents | (40) | (4,713) | |||
| Cash and cash equivalents at the beginning of the year | 16,961 | 21,674 | |||
| Cash and cash equivalents at the end of the year | \$ | 16,921 | \$ | 16,961 | |
| (a) Significant non cash transactions: | |||||
| Purchase of property and equipment on credit | - | 23 | |||
| Recognition of new lease liability and right-of-use | 587 | 48 | |||
| Termination of lease liability and right-of-use | (64) | (51) |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.